NYMOX PHARMACEUTICAL CORPORATION Interest Revenue Expense
NYMOX PHARMACEUTICAL CORPORATION (NYMXF) reported Interest Revenue Expense of -$8.00 thousand for the 3-month period ending 2020-06-30, per its 6-K filed 2020-08-14.
Discontinued › Expense Statement › Operating Expenses
ifrs-full:InterestRevenueExpense · last filed 2020-08-14
- NYMOX PHARMACEUTICAL CORPORATION interest revenue expense for the quarter ending 2020-06-30 was -$8.00K, a 113.11% decline year-over-year.
- NYMOX PHARMACEUTICAL CORPORATION interest revenue expense for the quarter ending 2020-03-31 was $25.00K, a 52.83% decline year-over-year.
- NYMOX PHARMACEUTICAL CORPORATION interest revenue expense for the quarter ending 2019-06-30 was $61.00K.
- NYMOX PHARMACEUTICAL CORPORATION interest revenue expense for the quarter ending 2019-03-31 was $53.00K.
| Period end | Interest Revenue Expense 3 month | Interest Revenue Expense 6 month |
|---|---|---|
| 2020-06-30 | -$8.00K 6-K · filed 2020-08-14 | $13.00K 6-K · filed 2020-08-14 |
| 2020-03-31 | $25.00K 6-K · filed 2020-05-14 | |
| 2019-06-30 | $61.00K 6-K · filed 2020-08-14 | $111.00K 6-K · filed 2020-08-14 |
| 2019-03-31 | $53.00K 6-K · filed 2020-05-14 |